Deals
Having secured deals with AstraZeneca and Novartis, Niowave is constructing a second facility to meet rising demand for actinium-225, which can be used to develop next-generation radiopharmaceuticals.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
A day after Illinois-based Aptinyx strengthened its relationship with pharma giant Allergan, the company is now eying an $80 million initial public offering of stock on the Nasdaq Exchange.
AveXis, a Novartis company based in Illinois, is investing $55 million to build a new manufacturing facility in Durham, North Carolina.
Verrica Pharmaceuticals, headquartered in West Chester, Pennsylvania, is launching an initial public offering (IPO), hoping to raise $86 million.
With the acquisition of Dublin-based Shire by Japan-based Takeda Pharmaceutical pretty much a done-deal, Takeda appears to be getting its financial house in order before it closes.
Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right.
The third time is the charm for AstraZeneca and its hyperkalemia treatment that has been dogged by manufacturing issues. After multiple rejections, the U.S. Food and Drug Administration finally gave its approval for the treatment.
MeiraGTx has filed with the U.S. Securities and Exchange Commission (SEC) its intentions to launch an initial public offering (IPO).
Only days after Eli Lilly and Company agreed to pay $1.6 billion for ARMO BioSciences, the Indianapolis-based drug company is acquiring AurKa Pharma, an oncology company.
The ink is still drying on the contracts for Japan’s Takeda Pharmaceutical’s acquisition of Dublin-based Shire for about $62.2 billion, but company executives are sharing some of the “inside baseball” about what went on behind the scenes of the deal.
Earlier this week Amneal Pharmaceuticals and Impax Laboratories completed their business merger, forming the new Amneal Pharmaceuticals. The combined companies are now the fifth largest generics business in the United States.